Meta-Analysis of Randomized Controlled Trials on Treatment of Pulmonary Arterial Hypertension

作者：Bing He, Fengwen Zhang, Xueying Li, Chaoshu Tang, Guosheng Lin, Junbao Du, Hongfang Jin · 发表于：Circulation Journal · 年份：2010 · DOI：10.1253/circj.cj-09-0971 · 被引用次数：49 · 研究领域：Pulmonary Hypertension Research and Treatments、Phosphodiesterase function and regulation、Cancer Research and Treatment

BACKGROUND: The aim of the present meta-analysis was to evaluate the efficacy and safety of treating pulmonary arterial hypertension (PAH) with inhaled iloprost, oral bosentan and sildenafil. METHODS AND RESULTS: The randomized controlled trials on the 3 drugs and placebo were retrieved from the databases MEDLINE, EMBASE, BIOSIS Previews and CNKI up to August 2009. In total 11 studies and 1,391 patients were selected. Compared with placebo, iloprost, bosentan and sildenafil reduced clinical worsening significantly (odds ratio [OR] =0.33, 95% confidence interval [CI] =0.22-0.49, P<0.00001), improved New York Heart Association/World Health Organization functional class (OR =2.81, 95%CI =1.95-4.03, P<0.00001), increased the 6-min walk test by 33.19 m, reduced systolic pulmonary arterial pressure, mean pulmonary arterial pressure and pulmonary vascular resistance, increased the cardiac index by 0.40 L x min(-1) x m(-2) and increased the cardiac output by 0.53 L/min. The incidence of serious adverse events was similar in the medication groups and the placebo group (OR =1.09, 95%CI =0.69-1.71, P=0.72). In terms of the clinical worsening and functional class amelioration, insignificant differences were found among iloprost, bosentan and sildenafil, but iloprost had the highest incidence of serious adverse events among the 3 drugs. CONCLUSIONS: Inhaled iloprost and oral bosentan and sildenafil are effective and safe in treating PAH.